Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,358 stopped studies mapped to Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,358 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00009984 | Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer | Phase 2 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01238146 | Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With… | Phase 1 / Phase 2 | withdrawn | Nov 10, 2010 | National Cancer Institute (NCI) | No patients accrued. | Enrollment / accrual |
| NCT00103272 | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With… | Phase 1 | terminated | Feb 8, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00126191 | Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma | Phase 2 | terminated | Aug 3, 2005 | Dana-Farber Cancer Institute | closed due to slow accrual | Enrollment / accrual |
| NCT00354185 | PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic… | Phase 1 | terminated | Jul 20, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00801918 | Denileukine Diftitox for Relapsed ALCL | Phase 2 | withdrawn | Dec 4, 2008 | Columbia University | Lack of funding | Funding |
| NCT00558727 | Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | Phase 1 | terminated | Nov 15, 2007 | Spectrum Pharmaceuticals, Inc | not stated | Not stated |
| NCT00968396 | Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts | Phase 2 | withdrawn | Aug 31, 2009 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT01179490 | Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma | Phase 2 | terminated | Aug 11, 2010 | SymBio Pharmaceuticals | not stated | Not stated |
| NCT01667289 | Radiotherapy Alone Versus Concurrent Chemoradiation in Low Risk NK/T-cell Lymphoma | Phase 2 | terminated | Aug 17, 2012 | Fudan University | unexpected high grade of mucositis observed | Other (stated, no rule matched) |
| NCT01680796 | Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple… | Phase 1 | withdrawn | Sep 7, 2012 | University of Florida | The target drug, dovitinib, failed as a single agent in prior studies in patients with heavily… | Other (stated, no rule matched) |
| NCT00005786 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia | N/A | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00452127 | A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or… | Phase 1 / Phase 2 | terminated | Mar 27, 2007 | Genentech, Inc. | not stated | Not stated |
| NCT01266811 | A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in… | Phase 3 | withdrawn | Dec 24, 2010 | Centocor, Inc. | Study canceled based on results of different study with similar hypothesis, investigational agent,… | Other (stated, no rule matched) |
| NCT00015912 | Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory… | Phase 2 | terminated | Oct 15, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00060112 | Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma | Phase 1 | terminated | May 7, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00005950 | 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell… | Phase 2 | terminated | Apr 20, 2004 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00005982 | 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma | Phase 2 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00036855 | Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00030381 | Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis | Phase 1 | terminated | Sep 17, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00052377 | Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides | Phase 1 / Phase 2 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00101244 | SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's… | Phase 1 | terminated | Jan 10, 2005 | National Cancer Institute (NCI) | Administratively Complete. | Other (stated, no rule matched) |
| NCT00003613 | O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01234974 | IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus | Phase 2 | withdrawn | Nov 4, 2010 | Milton S. Hershey Medical Center | Study never undertaken | Other (stated, no rule matched) |
| NCT00301795 | Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV… | Phase 2 | terminated | Mar 13, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00902525 | Zevalin Twice in Aggressive Non-Hodgkin Lymphoma | Phase 2 | terminated | May 15, 2009 | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie | After enrolling 25 patients an interim analysis was done.The study was discontinued in the absence… | Efficacy / futility |
| NCT00850499 | Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in… | Phase 2 | terminated | Feb 25, 2009 | Millennium Pharmaceuticals, Inc. | not stated | Not stated |
| NCT00541424 | Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma | — | withdrawn | Oct 10, 2007 | M.D. Anderson Cancer Center | No study recruitment due to time constraints and lack of support. | Enrollment / accrual |
| NCT00361621 | Ph II CHOP+Velcade in Mediastinal LBCL | Phase 2 | terminated | Aug 8, 2006 | Dana-Farber Cancer Institute | Closed due to slow accrual | Enrollment / accrual |
| NCT00636155 | EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Phase 2 | terminated | Mar 14, 2008 | David Rizzieri | funding | Funding |
| NCT00699296 | Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell… | Phase 2 | terminated | Jun 17, 2008 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT00058773 | Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed…(ANGELA) | Phase 1 | terminated | Apr 15, 2003 | Baylor College of Medicine | not stated | Not stated |
| NCT00742495 | Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or…(BCX1777-108) | Phase 1 / Phase 2 | terminated | Aug 27, 2008 | Mundipharma Research Limited | Slow Recruitment | Enrollment / accrual |
| NCT01300793 | Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide(V-RICE) | Phase 1 | terminated | Feb 23, 2011 | University of California, San Francisco | closed for low accrual and no data is available. | Enrollment / accrual |
| NCT00969085 | Trial of Curcumin in Cutaneous T-cell Lymphoma Patients | Phase 2 | withdrawn | Aug 31, 2009 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT01269203 | Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple… | Phase 2 | withdrawn | Jan 4, 2011 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00793650 | Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC)… | Phase 1 / Phase 2 | terminated | Nov 19, 2008 | Emory University | not stated | Not stated |
| NCT00968331 | Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients… | Phase 2 | terminated | Aug 31, 2009 | University of Bologna | The EC withdrawn the approval becuase of possible conflicts of interests between our Institute and… | Other (stated, no rule matched) |
| NCT01036399 | Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell… | Phase 2 | terminated | Dec 21, 2009 | University of Bologna | The EC withdrawn the approval becuase of possible conflicts of interests between our Institute and… | Other (stated, no rule matched) |
| NCT00038818 | CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell… | N/A | terminated | Jun 7, 2002 | M.D. Anderson Cancer Center | Low accrual. | Enrollment / accrual |
| NCT00242827 | Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple… | Phase 2 | terminated | Oct 21, 2005 | Cephalon | not stated | Not stated |
| NCT00726869 | A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized… | Phase 1 | terminated | Aug 1, 2008 | Abbott | Enrollment has been halted | Enrollment / accrual |
| NCT01103388 | Rituximab Maintenance After Autologous Transplantation | Phase 3 | terminated | Apr 14, 2010 | M.D. Anderson Cancer Center | Closed early due to slow patient accrual and sponsor's withdrawal of support. | Enrollment / accrual |
| NCT00843050 | A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory… | Phase 2 | terminated | Feb 13, 2009 | Piramal Enterprises Limited | The study was terminated based on interim results and all subjects were off study at that time. No… | Safety / toxicity |
| NCT00127881 | Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome | Phase 3 | terminated | Aug 9, 2005 | Emergent Product Development Seattle LLC | New sponsor, other treatments available | Other (stated, no rule matched) |
| NCT00368121 | EMMA-1 (Erbitux for Multiple Myeloma)(EMMA-1) | Phase 2 | terminated | Aug 24, 2006 | Prof. Dr. Andreas Engert | Lack of recruitable patients | Enrollment / accrual |
| NCT01558778 | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem… | N/A | withdrawn | Mar 20, 2012 | Roswell Park Cancer Institute | device not available | Other (stated, no rule matched) |
| NCT00383097 | Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's…(ALDI) | Phase 1 | terminated | Oct 2, 2006 | Baylor College of Medicine | The trial was terminated in 2010 due to lack of enrollment. | Enrollment / accrual |
| NCT01492881 | Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory… | Phase 2 | withdrawn | Dec 15, 2011 | UNC Lineberger Comprehensive Cancer Center | Doxil is currently unavailable | Other (stated, no rule matched) |
| NCT00128921 | Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma | Phase 2 | terminated | Aug 10, 2005 | University of Arkansas | study terminated due to low accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jun 6, 2013source: clinicaltrials